ECOG-ACRIN BY THE NUMBERS

Loading Quotes...

Announcements

Read the latest issue of our News from ECOG-ACRIN blog

Cancer doesn’t stop for COVID, and neither should cancer screening or treatment Advocacy Blog

Our clinical trials are enrolling patients during the pandemic More Here

Question about COVID19? Send an email

Latest News

Amidst the ongoing COVID-19 pandemic, the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) continues to post strong monthly accrual. Read more.

 

 

 

Adjuvant therapy with sunitinib or sorafenib did not improve disease-free survival or overall survival in patients with sarcomatoid renal cell carcinoma, according to a post hoc analysis from study E2805 by Jose A. Karam, MD, FACS, and colleagues. September 4, 2021. British Journal of Urology International

 

Entinostat does not overcome endocrine resistance in advanced breast cancer, as Roisin Connolly and colleagues report in the final results of the E2112 trial. August 17, 2021. Cancer Therapy Advisor

 

 

Looking for more (older) news coverage? Visit the News and Info section and the TMIST Press Center.

 

Acknowledgments

Welcome

Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

 

Robert L. Comis, MD
Group Co-Chair


Mitchell D. Schnall, MD, PhD
Group Co-Chair
img img
img
img